ToBeSoft and IoneBio Promote Technology Collaboration in the AI Dental Bio Field

DX (Digital Transformation) solution specialist ToBeSoft announced on the 5th that it signed a business agreement for cooperation in the field of artificial intelligence (AI) dental bio with dental and bio convergence technology company IoneBio at ToBeSoft headquarters on the 27th of last month.

Through a memorandum of understanding (MOU), the two companies agreed to jointly promote the development of 3D oral scanner software based on ToBeSoft’s AI technology, the creation of a specialized platform for building oral digital big data, and the development of a platform for constructing genetic genome big data.

ToBeSoft has held the number one market share for 20 years by supplying UI/UX development platforms to Samsung, LG, Hyundai Motor, and others. Its flagship product, ‘Nexacro N,’ will be launched as ‘Nexacro N v24’ in November with new features. Additionally, it is creating new business opportunities by integrating its proprietary AI technology with Nexacro.

IoneBio is a dental bio R&D specialist company composed of 120 dentists as shareholders, developing various optical bio diagnostic medical devices including 3D oral scanners. Furthermore, Min Byung-moo, head of research (Emeritus Professor at Seoul National University, selected as one of the IBC World’s Top 100 Scientists), published clinical results of a new bone treatment drug material (VnP-16) in the 2022 International Journal of Periodontology and is accelerating research and development.

Global market research firm Statista forecasts that the global bone treatment drug market will reach 223 trillion KRW by 2030. Domestically, MBK Partners recently acquired oral scanner company Medit for 2.425 trillion KRW, indicating a very bright market outlook.

IoneBio plans to launch a prototype of a 3D oral scanner that can quickly and accurately scan, as well as diagnostic kits for stomatitis and oral cancer that can be easily used on-site, in the first half of next year.

Kim Kyung-han, Vice President of IoneBio, said, “Through this agreement, we can provide consumer-customized oral treatment solutions by integrating the latest IT technology and big data with optical bio diagnostic technology,” adding, “We will continue to introduce more effective technologies to the market.”

Lee Im-chan, CEO of ToBeSoft, said, “It is encouraging that ToBeSoft’s AI technology-based platform can now be applied to the medical field,” and added, “We will strive to ensure that more people benefit through oral treatment solutions and AI technology.” He continued, “We are preparing to make Nexacro available on the cloud from the end of this year and are expanding its use in the medical field,” and added, “We are receiving inquiries and providing consulting for companies aiming for digital transformation, establishing ourselves as a leading DX solution specialist company.”

This content was produced with the assistance of AI translation services.